Cabaletta Bio Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Cabaletta Bio kazanç ve gelirin sırasıyla yıllık 33.5% ve 72.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 36.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -80.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

33.5%

Kazanç büyüme oranı

36.86%

EPS büyüme oranı

Biotechs kazanç büyümesi	25.5%
Gelir büyüme oranı	72.2%
Gelecekteki özkaynak getirisi	-80.41%
Analist kapsamı	Good
Son güncelleme	18 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Mar 24

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Summary I am buying Cabaletta Bio shares as a speculative play on upcoming clinical trial updates for innovative CAR-T therapies. Despite high volatility in 2024 and the potential for total investment loss, the company’s strong cash position and lack of recent selling point to a bullish outlook. Super-positive testing results announced in mid-November would trigger significant stock gains, with the possibility of oversized returns on investment similar to 2022-23. I rate Cabaletta a Buy for a 12-month outlook, assuming a position size of less than 1% of net portfolio assets, to adequately offset greater-than-normal risk. Read the full article on Seeking Alpha

Analiz Makalesi • Sep 04

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Jun 28

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Summary Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug with the same MoA as CABA-201, showing remarkable results with many patients experiencing full recoveries. Cabaletta stock has been sinking in 2024 however due to slow progress, manufacturing concerns, and disappointing recent data release. Cabaletta plans to continue studies on CABA-201 for various autoimmune conditions, with the next data update due before the end of the year. The next data readout feels crucial - signs of efficacy will be greeted with a surge in share price value, but poor results could drive it back into delisting territory. There is all to play for. Read the full article on Seeking Alpha

Analiz Makalesi • May 22

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Jan 31

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Summary Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with myositis, is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with generalized myasthenia gravis, is expected in the 2nd half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic sclerosis, is expected in the 2nd half of 2024. Read the full article on Seeking Alpha

Analiz Makalesi • Dec 28

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. By way of example, Cabaletta Bio...

Analiz Makalesi • Sep 12

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...

Analiz Makalesi • Jun 04

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example...

Analiz Makalesi • Feb 11

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...

Analiz Makalesi • Oct 20

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Jul 07

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:CABA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	56	-240	-217	-286	8
12/31/2027	N/A	-225	-217	-224	7
12/31/2026	N/A	-188	-168	-163	7
3/31/2026	N/A	-175	-143	-143	N/A
12/31/2025	N/A	-168	-132	-131	N/A
9/30/2025	N/A	-159	-120	-119	N/A
6/30/2025	N/A	-144	-106	-105	N/A
3/31/2025	N/A	-127	-97	-95	N/A
12/31/2024	N/A	-116	-90	-88	N/A
9/30/2024	N/A	-104	-84	-82	N/A
6/30/2024	N/A	-90	-76	-74	N/A
3/31/2024	N/A	-77	-66	-65	N/A
12/31/2023	N/A	-68	-54	-54	N/A
9/30/2023	N/A	-62	-50	-49	N/A
6/30/2023	N/A	-57	-48	-47	N/A
3/31/2023	N/A	-56	-49	-46	N/A
12/31/2022	N/A	-53	-49	-46	N/A
9/30/2022	N/A	-51	-47	-45	N/A
6/30/2022	N/A	-51	-45	-43	N/A
3/31/2022	N/A	-50	-39	-38	N/A
12/31/2021	N/A	-46	-35	-34	N/A
9/30/2021	N/A	-42	-34	-33	N/A
6/30/2021	N/A	-39	-30	-29	N/A
3/31/2021	N/A	-36	-31	-31	N/A
12/31/2020	N/A	-33	-27	-27	N/A
9/30/2020	N/A	-29	-26	-25	N/A
6/30/2020	N/A	-26	-23	-23	N/A
3/31/2020	N/A	-21	-19	-19	N/A
12/31/2019	N/A	-22	N/A	-16	N/A
9/30/2019	N/A	-19	N/A	-10	N/A
6/30/2019	N/A	-23	N/A	-9	N/A
3/31/2019	N/A	-21	N/A	-6	N/A
12/31/2018	N/A	-12	N/A	-5	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CABA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: CABA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: CABA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: CABA gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: CABA gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CABA 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/20 08:17
Gün Sonu Hisse Fiyatı	2026/05/20 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Cabaletta Bio, Inc. 15 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Joshua Schimmer	Cantor Fitzgerald & Co.
Samantha Lynn Semenkow	Citigroup Inc
Joshua Schimmer	Evercore ISI

Cabaletta Bio Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 9.9% to US$14.43

Price target decreased by 7.1% to US$13.13

Price target increased by 9.6% to US$14.13

Price target decreased by 23% to US$12.00

Price target decreased by 16% to US$18.60

Price target increased by 8.5% to US$30.38

Recent updates

Cabaletta Bio, Inc. Announces the Appointment of Francisco Ramírez-Valle to Scientific Advisory Board

Price target increased by 9.9% to US$14.43

Cabaletta Bio, Inc. Presents New Clinical and Translational Data from Reset-Pv and Reset-Sle Trials

Cabaletta Bio Raises US$150 Million to Advance Autoimmune Cell Therapy After Encouraging Early Data

Cabaletta Bio, Inc. has completed a Follow-on Equity Offering in the amount of $150.0025 million.

Cabaletta Bio, Inc. Announces Multiple Upcoming Presentations Including Data On Rese-cel Without Preconditioning And Rese-cel With Automated Manufacturing

Cabaletta Bio, Inc., Annual General Meeting, Jun 09, 2026

Cabaletta Bio Inc. Doses First Patients With Rese-Cel Manufactured On Cellares' Automated Cell Shuttle Platform

Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely?

Cabaletta Bio: Do You Buy With The Insiders?

Co-Founder recently bought US$101k worth of stock

Cabaletta Bio Receives FDA Clearance of an IND Amendment to Use Cellares' Cell Shuttle and Cell Q Platforms

Price target decreased by 7.1% to US$13.13

New major risk - Financial position

Price target increased by 9.6% to US$14.13

Cabaletta Bio, Inc. Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

Cabaletta Bio, Inc. Announces the Appointment of Steve Gavel as Chief Commercial Officer, Effective from October 14, 2025

New major risk - Revenue and earnings growth

Cabaletta Bio, Inc. Presents First Rese-cel Data with No Pre Conditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

Price target decreased by 23% to US$12.00

New major risk - Shareholder dilution

Cabaletta Bio, Inc.(NasdaqGS:CABA) dropped from Russell 2500 Value Index

Cabaletta Bio, Inc. has completed a Follow-on Equity Offering in the amount of $99.999892 million.

Cabaletta Bio, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Cabaletta Bio, Inc. Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Cabaletta Bio, Inc., Annual General Meeting, Jun 09, 2025

Cabaletta Bio, Inc. Auditor Raises 'Going Concern' Doubt

Price target decreased by 16% to US$18.60

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

New minor risk - Market cap size

Cabaletta Bio, Inc. Announces Updated Clinical Data Demonstrating Deepening Clinical Responses Across Multiple Indications with Rese-cel at February Scientific Meetings

Cabaletta Bio: Finding Optimism In Dire Straits

Insufficient new directors

Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth?

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

New major risk - Revenue and earnings growth

New major risk - Share price stability

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

New major risk - Revenue and earnings growth

Cabaletta Bio, Inc., Annual General Meeting, Jun 03, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Cabaletta Bio, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

President of Science & Technology exercised options and sold US$204k worth of stock

Cabaletta Bio, Inc. Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

President of Science & Technology exercised options and sold US$230k worth of stock

President of Science & Technology notifies of intention to sell stock

Price target increased by 8.5% to US$30.38

Cabaletta Bio, Inc. Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis

President of Science & Technology exercised options and sold US$136k worth of stock

Cabaletta Bio, Inc. Receives U.S. Food and Drug Administration Clearance of Investigational New Drug Application for Treatment of Systemic Sclerosis with CABA-201

President of Science & Technology notifies of intention to sell stock

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

President of Science & Technology exercised options and sold US$136k worth of stock

Cabaletta Bio, Inc. Appoints Shawn Tomasello to Its Board of Directors

President of Science & Technology notifies of intention to sell stock

New major risk - Revenue and earnings growth

Price target increased by 26% to US$17.00

President of Science & Technology exercised options and sold US$132k worth of stock

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation